Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment and outcomes of primary breast lymphoma.
Caon J, Wai ES, Hart J, Alexander C, Truong PT, Sehn LH, Connors JM. Caon J, et al. Among authors: hart j. Clin Breast Cancer. 2012 Dec;12(6):412-9. doi: 10.1016/j.clbc.2012.07.006. Epub 2012 Sep 25. Clin Breast Cancer. 2012. PMID: 23018097
Utilization of Mutational Analysis (MA) in Gastrointestinal Stromal Tumor (GIST) Management in British Columbia (BC) Between January 2008 to December 2017: a Retrospective Population-Based Study.
Patterson T, Chai J, Li H, de Bruyns A, Cleversey C, Lee CH, Yip S, Simmons C, Hart J, Pollock P, Holloway C, Truong P, Feng X. Patterson T, et al. Among authors: hart j. J Gastrointest Cancer. 2022 Sep;53(3):709-717. doi: 10.1007/s12029-021-00682-2. Epub 2021 Sep 6. J Gastrointest Cancer. 2022. PMID: 34486087
Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic.
Ksienski D, Gupta S, Truong PT, Bone J, Chan A, Alex D, Hart J, Pollock P, Patterson T, Clarkson M, Dissanayake D, Sonke E, Lesperance M. Ksienski D, et al. Among authors: hart j. J Cancer Res Clin Oncol. 2023 Jul;149(7):2951-2961. doi: 10.1007/s00432-022-04181-0. Epub 2022 Jul 14. J Cancer Res Clin Oncol. 2023. PMID: 35834010 Free PMC article.
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic.
Lakkunarajah S, Truong PT, Bone JN, Hughesman C, Yip S, Alex D, Hart J, Pollock P, Egli S, Clarkson M, Lesperance M, Ksienski D. Lakkunarajah S, et al. Among authors: hart j. Transl Lung Cancer Res. 2023 Jul 31;12(7):1454-1465. doi: 10.21037/tlcr-23-81. Epub 2023 Jul 21. Transl Lung Cancer Res. 2023. PMID: 37577326 Free PMC article.
3,100 results